Abbott (ABT) announced results from the FreeDM2 randomized controlled trial showing that people using FreeStyle Libre continuous glucose monitoring technology had better glucose outcomes than those using traditional fingersticks. The trial was designed to determine whether real-time continuous glucose monitoring can help people using basal insulin improve their glucose management.
In the U.K. FreeDM2 randomized controlled trial, at four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks. Complementary Italian study reported similar improvements, the company said.
In pre-market trading on NYSE, Abbott shares are down 0.61 percent to $109.57.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.